Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free ALMR Stock Alerts

Alamar Biosciences (ALMR) Competitors

$25.88 -0.01 (-0.04%)
As of 07/24/2026 04:00 PM Eastern
Compare

ALMR vs. CAMT, ST, TXG, VNT, and MIR

Should you buy Alamar Biosciences stock or one of its competitors? MarketBeat compares Alamar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alamar Biosciences include Camtek (CAMT), Sensata Technologies (ST), 10x Genomics (TXG), Vontier (VNT), and Mirion Technologies (MIR). These companies are all part of the "measuring and control equipment" industry.

How does Alamar Biosciences compare to Camtek?

Camtek (NASDAQ:CAMT) and Alamar Biosciences (NASDAQ:ALMR) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Camtek has a net margin of 9.63% compared to Alamar Biosciences' net margin of 0.00%. Camtek's return on equity of 22.26% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Camtek9.63% 22.26% 11.70%
Alamar Biosciences N/A N/A N/A

Camtek currently has a consensus target price of $174.67, suggesting a potential upside of 18.19%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 15.92%. Given Camtek's higher probable upside, equities analysts clearly believe Camtek is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Camtek
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alamar Biosciences
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

41.9% of Camtek shares are owned by institutional investors. 79.4% of Camtek shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Camtek had 5 more articles in the media than Alamar Biosciences. MarketBeat recorded 6 mentions for Camtek and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat Camtek's score of 0.90 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Camtek Positive
Alamar Biosciences Very Positive

Camtek has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Camtek$496.07M13.90$50.72M$0.87169.87
Alamar Biosciences$87.16M20.58-$120.60M-$1.74N/A

Summary

Camtek beats Alamar Biosciences on 12 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Sensata Technologies?

Sensata Technologies (NYSE:ST) and Alamar Biosciences (NASDAQ:ALMR) are both measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Sensata Technologies has a net margin of 1.28% compared to Alamar Biosciences' net margin of 0.00%. Sensata Technologies' return on equity of 18.23% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sensata Technologies1.28% 18.23% 7.34%
Alamar Biosciences N/A N/A N/A

Sensata Technologies has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Sensata Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensata Technologies$3.70B1.79$31.30M$0.31147.16
Alamar Biosciences$87.16M20.58-$120.60M-$1.74N/A

In the previous week, Sensata Technologies had 10 more articles in the media than Alamar Biosciences. MarketBeat recorded 11 mentions for Sensata Technologies and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat Sensata Technologies' score of 0.89 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Sensata Technologies Positive
Alamar Biosciences Very Positive

Sensata Technologies presently has a consensus price target of $48.60, suggesting a potential upside of 6.53%. Alamar Biosciences has a consensus price target of $30.00, suggesting a potential upside of 15.92%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Sensata Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensata Technologies
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Alamar Biosciences
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

99.4% of Sensata Technologies shares are owned by institutional investors. 0.7% of Sensata Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Sensata Technologies beats Alamar Biosciences on 10 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Alamar Biosciences (NASDAQ:ALMR) are both measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

10x Genomics currently has a consensus target price of $32.08, suggesting a potential downside of 30.66%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 15.92%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Alamar Biosciences is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Alamar Biosciences
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

10x Genomics has higher revenue and earnings than Alamar Biosciences. 10x Genomics is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$638.78M9.20-$43.54M-$0.17N/A
Alamar Biosciences$87.16M20.58-$120.60M-$1.74N/A

In the previous week, 10x Genomics had 6 more articles in the media than Alamar Biosciences. MarketBeat recorded 7 mentions for 10x Genomics and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat 10x Genomics' score of 0.98 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
10x Genomics Positive
Alamar Biosciences Very Positive

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alamar Biosciences has a net margin of 0.00% compared to 10x Genomics' net margin of -3.55%. Alamar Biosciences' return on equity of 0.00% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-3.55% -2.86% -2.23%
Alamar Biosciences N/A N/A N/A

Summary

Alamar Biosciences beats 10x Genomics on 8 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to Vontier?

Alamar Biosciences (NASDAQ:ALMR) and Vontier (NYSE:VNT) are both measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Alamar Biosciences currently has a consensus price target of $30.00, indicating a potential upside of 15.92%. Vontier has a consensus price target of $41.89, indicating a potential upside of 36.11%. Given Vontier's higher probable upside, analysts plainly believe Vontier is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alamar Biosciences
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Vontier
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45

95.8% of Vontier shares are held by institutional investors. 1.1% of Vontier shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vontier has a net margin of 13.37% compared to Alamar Biosciences' net margin of 0.00%. Vontier's return on equity of 37.88% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alamar BiosciencesN/A N/A N/A
Vontier 13.37%37.88%10.90%

Vontier has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alamar Biosciences$87.16M20.58-$120.60M-$1.74N/A
Vontier$3.09B1.40$406.10M$2.8310.87

In the previous week, Vontier had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 5 mentions for Vontier and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat Vontier's score of 0.81 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Alamar Biosciences Very Positive
Vontier Positive

Summary

Vontier beats Alamar Biosciences on 12 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Mirion Technologies?

Alamar Biosciences (NASDAQ:ALMR) and Mirion Technologies (NYSE:MIR) are both measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

In the previous week, Mirion Technologies had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 9 mentions for Mirion Technologies and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat Mirion Technologies' score of 0.73 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Alamar Biosciences Very Positive
Mirion Technologies Positive

78.5% of Mirion Technologies shares are held by institutional investors. 6.3% of Mirion Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mirion Technologies has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Mirion Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alamar Biosciences$87.16M20.58-$120.60M-$1.74N/A
Mirion Technologies$981M4.22$28.80M$0.10165.24

Mirion Technologies has a net margin of 2.56% compared to Alamar Biosciences' net margin of 0.00%. Mirion Technologies' return on equity of 6.44% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alamar BiosciencesN/A N/A N/A
Mirion Technologies 2.56%6.44%3.48%

Alamar Biosciences currently has a consensus price target of $30.00, suggesting a potential upside of 15.92%. Mirion Technologies has a consensus price target of $27.00, suggesting a potential upside of 63.40%. Given Mirion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Mirion Technologies is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alamar Biosciences
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Mirion Technologies
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Summary

Mirion Technologies beats Alamar Biosciences on 14 of the 16 factors compared between the two stocks.

Get Alamar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALMR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALMR vs. The Competition

Export
MetricAlamar BiosciencesLab Analytical Instruments IndustryManufacturing SectorNASDAQ Exchange
Market Cap$1.79B$1.79B$7.24B$12.28B
Dividend YieldN/AN/A40.99%9.79%
P/E Ratio-14.87N/A23.6223.71
Price / Sales20.5820.58160.9975.28
Price / CashN/AN/A165.0159.64
Price / BookN/AN/A12.776.07
Net Income-$120.60MN/A$120.21M$331.99M
7 Day Performance-0.27%-0.27%-0.98%-0.63%
1 Month Performance-3.68%-3.68%-2.00%-2.00%
1 Year PerformanceN/AN/A9.75%13.62%

Alamar Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALMR
Alamar Biosciences
3.3769 of 5 stars		$25.88
0.0%		$30.00
+15.9%		N/A$1.79B$87.16MN/A222
CAMT
Camtek
4.0587 of 5 stars		$146.15
-1.2%		$174.67
+19.5%		+56.8%$6.82B$496.07M167.99400
ST
Sensata Technologies
2.9646 of 5 stars		$45.05
+1.4%		$48.60
+7.9%		+40.3%$6.55B$3.70B145.3316,700
TXG
10x Genomics
1.8955 of 5 stars		$43.74
-1.7%		$32.08
-26.6%		+237.0%$5.55B$642.82MN/A1,240
VNT
Vontier
4.1682 of 5 stars		$30.39
-0.7%		$41.89
+37.8%		-21.0%$4.27B$3.08B10.747,800

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALMR) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel